Anticoagulants Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2026

Published on : Nov-2019 | List of Tables : 30 | List of Figures : 83 | No. of Pages : 170 | Report Code : FACT4335MR | Format : ppt pdf Excel Word

Manufacturers’ Reliance on R&D Activities to Remain High in Anticoagulants Market

The emergence of online pharmacies is influencing the increasing sales of anticoagulant drugs. Players operating in the anticoagulants market are progressively adopting online sales channels to broaden their reach with low capital investment. On the demand side, surging incidence of heart attacks, on the backdrop of unhealthy lifestyles adopted by individuals, is projected to widen the patient pool for the anticoagulants market during the forecast period (2020-2026). The demand for anticoagulants has also recorded a notable growth from developing countries, given the financial support offered by central authorities to revamp healthcare facilities and upgrade service quality.

Sensing high growth prospects of the anticoagulants market, leading players are leveraging research & development activities, which is increasing the number of pipeline drugs. All-in-all, the anticoagulants market is expected to witness a healthy growth, with an estimated CAGR of ~8% during the forecast period.

key segments anticoagulants market

For detailed insights on market taxonomy, request a sample copy of the report here.

Conventional Hold of Warfarin Could Negatively Impact Sales of Anticoagulants

The popularity of conventional drugs such as warfarin is high, especially in developing countries, owing to their cost-benefits. The monthly cost of generic warfarin is in the range of ~US$ 16 t0 ~US$ 20, while that of a monthly supply of NOAC is tantamount to ~US$ 70. Given this influence, the demand for advanced anticoagulants is likely to get impeded during the forecast period. In addition, these drugs are used for long-term treatment, which requires individuals to allocate an additional budget for these advanced drugs for a long duration. As a result, individuals residing in India, China, Brazil, and similar developing countries are showing reluctance in buying advanced anticoagulants.

Another aspect that players in the anticoagulants market need to focus on is increasing awareness about the side effects caused by the consumption of NOACs. Patients undergoing treatment of anticoagulant disorders have reported side effects of NOAC, which include excessive bleeding, vomiting, and nausea. Despite having fewer side effects than conventional drugs, the acceptance of NOAC is low, thereby limiting the growth prospects of the anticoagulants market during the forecast period.

Patent-Assistance Programs to Underpin Adoption of Anticoagulants

Players in the anticoagulants market are coming forward to shoulder the financial burden of individuals through patient-assistance programs, as an instrument to boost the exposure of anticoagulants. For instance, Bristol-Myers Squibb offers financial aid to patients to purchase medicines through the company’s foundation. However, the program offers assistance only to individuals who are residents of the U.S. and not insured by any privately- or publicly-held company. Besides this, Boehringer Ingelheim offers the PRADAXA savings card to buy medicines at minimum rates. Increase in the number of manufacturers taking financial initiatives is projected to boost the adoption of drugs during the forecast period.

opportunity analysis for drug class anticoagulants market

For detailed regional analysis, request a sample copy of the report here.

Prominence of Heparins to Remain High in Developing Countries of Asia Pacific

In 2020, ~54% of sales of the total North American anticoagulants market are projected to arrive from cases of atrial fibrillation and heart attacks, and factor XA inhibitors will remain the preferred drug class. On a global level, the U.S. is found to have the highest obesity rate, with Canada occupying a position in the top 10 most obese countries across the world. Given the direct correlation between obesity and heart diseases, the sales of anticoagulants are high in the U.S., and are projected to grow during the forecast period. The high technological prowess of players operating in the North American anticoagulants market offers them an edge to produce effective drugs with utmost precision, which further accelerates the momentum of the regional market.

In contrast to this, healthcare facilities in Asia Pacific have transformed only recently, which has been drawing the attention of individuals towards the significance of ideal health. Central authorities and key healthcare organizations are devising guidelines to endorse the use of certain types of drugs to control anticoagulant disorders, which is boosting the growth of the Asia Pacific anticoagulants market. A shift from conventional heparins to factor XA inhibitors is seen in the developed countries of this region; however, the popularity of heparins is projected to remain high in developing countries during the forecast period.

Request research methodology of this report.

Anticoagulants Market – Scope of the Study

The study on the anticoagulants market is an exclusive report published by Fact.MR, which highlights the key parameters that are influencing the growth of the landscape. This study offers insights on the growth of the anticoagulants market, by analysing the historical data for the period of 2016-2019, and 2020-2026 as the forecast period. Estimation of the revenue of the anticoagulants market has been carried out in terms of value (US$ Mn). This research highlights the key trends that hold the potential to influence the growth of the anticoagulants market, along with crucial macroeconomic and microeconomic growth indicators. This insightful report offers the key dynamics, and their impact on the value chain, which are projected to influence the future growth of the anticoagulants market.

The study also includes a detailed section dedicated to impeders that could challenge the growth of players in the anticoagulants market. The report unfolds lucrative opportunities for market players, which they can leverage to consolidate their position in the global market. With a view of aiding stakeholders in the anticoagulants market, the study comprises a detailed section on the competition analysis. The study offers a dashboard view of the report, with a comprehensive comparison of players operating in the anticoagulants market, based on total revenue, market presence, and key developments. Besides this, the recent developments and key strategies of players in the anticoagulants market have also been included in this comprehensive study.

Anticoagulants Market – Assessment of Key Segments

Authors of the report have segmented the anticoagulants market into key categories in order to study the market at a microscopic level. The key segments considered while bifurcating the anticoagulants market include:

Drug Class

Indication

Route of Administration

Distribution Channel

Region

Factor XA Inhibitors (NOAC/DOAC)

Deep Vein Thrombosis

Oral

Hospital Pharmacies

North America

Heparins

Pulmonary Embolism

Injectable

Retail Pharmacies

Latin America

Direct Thrombin Inhibitors

Atrial Fibrillation & Heart Attack

 

Online Pharmacies

Europe

Vitamin K Antagonists

Others

 

 

Asia Pacific

 

 

 

 

Middle East & Africa

Besides laying focus on the aforementioned key segments, the report also studies the anticoagulants market at a country level, to recalibrate the underlying opportunities available for players in the anticoagulants market for the forecast period. Among all the estimated data, the report also includes Y-o-Y growth projections, which can help market players in comprehending the precise trajectory at which the anticoagulants market has been growing.

Key companies profiled in this exclusive study include Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Sanofi, and Johnson & Johnson Service. The study provides crucial insights into the finances of these companies, along with their product portfolios, key strategies, and SWOT analysis. In addition, the study also discusses Porter’s Five Forces, which highlights the threats of substitutes, purchasing power of buyers and suppliers, and intensity of competition present in the anticoagulants market during the forecast period (2020-2026).

Anticoagulants Market – Research Methodology

The anticoagulants market has been evaluated by taking a top-down and bottom-up approach. Demand, geographical presence, distribution strategies by manufacturers, and initiatives taken by governments and NGOs are various factors considered while estimating the revenue of the anticoagulants market, and thus, reaching global numbers. The study on the anticoagulants market is further validated through extensive primary research on the data extracted from exhaustive secondary research.

In order to conduct secondary research, annual company reports, company websites, data from the World Health Organization (WHO), SEC filings, press releases, investor presentations, and other similar resources were studied. To validate the information compiled through secondary research, interviews with key opinion leaders and subject matter experts were scheduled. In addition to this, authors of the report also had email and telephonic interactions with the senior management of leading and prominent companies, to confirm the size, growth trend, and future outlook of the anticoagulants market.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Anticoagulants Market 

4. Market Overview

    4.1. Introduction

        4.1.1. Route of Administration Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

        4.3.4. Market Trends 

    4.4. Global Anticoagulants market analysis and Forecast, 2016–2026

    4.5. Porter’s Five Force Analysis

5. Market Outlook

    5.1. Key Mergers & Acquisitions 

6. Global Anticoagulants Market Analysis and Forecast, by Route of Administration 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Route of Administration, 2016–2026

        6.3.1. Oral

        6.3.2. Injectable

    6.4. Market Attractiveness, by Route of Administration

7. Global Anticoagulants Market Analysis and Forecast, by Drug Class

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Drug Class, 2016–2026

        7.3.1. Factor XA Inhibitors (NOAC/DOAC)

        7.3.2. Heparins

        7.3.3. Direct Thrombin Inhibitors

        7.3.4. Vitamin K Antagonists

    7.4. Market Attractiveness, by Drug Class

8. Global Anticoagulants Market Analysis and Forecast, by Indication

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Distribution Channel, 2016–2026

        8.3.1. Deep Vein Thrombosis

        8.3.2. Pulmonary Embolism

        8.3.3. Atrial Fibrillation & Heart Attack

        8.3.4. Others

    8.4. Market Attractiveness, by Distribution Channel 

9. Global Anticoagulants Market Analysis and Forecast, by Distribution Channel 

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Market Value Forecast, by Distribution Channel, 2016–2026

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies

        9.3.3. Online Pharmacies

    9.4. Market Attractiveness, by Distribution Channel 

10. Global Anticoagulants Market Analysis and Forecast, by Region

    10.1. Key Findings

    10.2. Market Value Forecast, by Region

        10.2.1. North America 

        10.2.2. Europe 

        10.2.3. Asia Pacific 

        10.2.4. Latin America 

        10.2.5. Middle East & Africa

    10.3. Market Attractiveness, by Region

11. North America Anticoagulants Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Route of Administration, 2016–2026

        11.2.1. Oral

        11.2.2. Injectables

    11.3. Market Value Forecast, by Drug Class, 2016–2026

        11.3.1. Factor XA Inhibitors (NOAC/DOAC)

        11.3.2. Heparins

        11.3.3. Direct Thrombin Inhibitors

        11.3.4. Vitamin K Antagonists

    11.4. Market Value Forecast, by Distribution Channel, 2016–2026

        11.4.1. Deep Vein Thrombosis

        11.4.2. Pulmonary Embolism

        11.4.3. Atrial Fibrillation & Heart Attack

        11.4.4. Others

    11.5. Market Value Forecast, by Distribution Channel, 2016–2026

        11.5.1. Hospital Pharmacies

        11.5.2. Retail Pharmacies

        11.5.3. Online Pharmacies

    11.6. Market Value Forecast, by Country, 2016–2026

        11.6.1. U.S.

        11.6.2. Canada

    11.7. Market Attractiveness Analysis 

        11.7.1. By Route of Administration 

        11.7.2. By Drug Class

        11.7.3. By Indication

        11.7.4. By Distribution Channel 

        11.7.5. By Country

12. Europe Anticoagulants Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Route of Administration, 2016–2026

        12.2.1. Oral

        12.2.2. Injectables

    12.3. Market Value Forecast, by Drug Class, 2016–2026

        12.3.1. Factor XA Inhibitors (NOAC/DOAC)

        12.3.2. Heparins

        12.3.3. Direct Thrombin Inhibitors

        12.3.4. Vitamin K Antagonists

    12.4. Market Value Forecast, by Distribution Channel, 2016–2026

        12.4.1. Deep Vein Thrombosis

        12.4.2. Pulmonary Embolism

        12.4.3. Atrial Fibrillation & Heart Attack

        12.4.4. Others

    12.5. Market Value Forecast, by Distribution Channel, 2016–2026

        12.5.1. Hospital Pharmacies

        12.5.2. Retail Pharmacies

        12.5.3. Online Pharmacies

    12.6. Market Value Forecast, by Country/Sub-region, 2016–2026

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Italy

        12.6.5. Spain

        12.6.6. Rest of Europe

    12.7. Market Attractiveness Analysis 

        12.7.1. By Route of Administration 

        12.7.2. By Drug Class

        12.7.3. By Indication

        12.7.4. By Distribution Channel 

        12.7.5. By Country/Sub-Region

13. Asia Pacific Anticoagulants Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Route of Administration, 2016–2026

        13.2.1. Oral

        13.2.2. Injectables

    13.3. Market Value Forecast, by Drug Class, 2016–2026

        13.3.1. Factor XA Inhibitors (NOAC/DOAC)

        13.3.2. Heparins

        13.3.3. Direct Thrombin Inhibitors

        13.3.4. Vitamin K Antagonists

    13.4. Market Value Forecast, by Distribution Channel, 2016–2026

        13.4.1. Deep Vein Thrombosis

        13.4.2. Pulmonary Embolism

        13.4.3. Atrial Fibrillation & Heart Attack

        13.4.4. Others

    13.5. Market Value Forecast, by Distribution Channel, 2016–2026

        13.5.1. Hospital Pharmacies

        13.5.2. Retail Pharmacies

        13.5.3. Online Pharmacies

    13.6. Market Value Forecast, by Country/Sub-region, 2016–2026

        13.6.1. Japan

        13.6.2. China

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific 

    13.7. Market Attractiveness Analysis 

        13.7.1. By Route of Administration 

        13.7.2. By Drug Class

        13.7.3. By Indication

        13.7.4. By Distribution Channel 

        13.7.5. By Country/Sub-Region

14. Latin America Anticoagulants Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Route of Administration, 2016–2026

        14.2.1. Oral

        14.2.2. Injectables

    14.3. Market Value Forecast, by Drug Class, 2016–2026

        14.3.1. Factor XA Inhibitors (NOAC/DOAC)

        14.3.2. Heparins

        14.3.3. Direct Thrombin Inhibitors

        14.3.4. Vitamin K Antagonists

    14.4. Market Value Forecast, by Distribution Channel, 2016–2026

        14.4.1. Deep Vein Thrombosis

        14.4.2. Pulmonary Embolism

        14.4.3. Atrial Fibrillation & Heart Attack

        14.4.4. Others

    14.5. Market Value Forecast, by Distribution Channel, 2016–2026

        14.5.1. Hospital Pharmacies

        14.5.2. Retail Pharmacies

        14.5.3. Online Pharmacies

    14.6. Market Value Forecast, by Country/Sub-region, 2016–2026

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Market Attractiveness Analysis 

        14.7.1. By Route of Administration 

        14.7.2. By Drug Class

        14.7.3. By Indication

        14.7.4. By Distribution Channel 

        14.7.5. By Country/Sub-Region

15. Middle East & Africa Anticoagulants Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Market Value Forecast, by Route of Administration, 2016–2026

        15.2.1. Oral

        15.2.2. Injectables

    15.3. Market Value Forecast, by Drug Class, 2016–2026

        15.3.1. Factor XA Inhibitors (NOAC/DOAC)

        15.3.2. Heparins

        15.3.3. Direct Thrombin Inhibitors

        15.3.4. Vitamin K Antagonists

    15.4. Market Value Forecast, by Distribution Channel, 2016–2026

        15.4.1. Deep Vein Thrombosis

        15.4.2. Pulmonary Embolism

        15.4.3. Atrial Fibrillation & Heart Attack

        15.4.4. Others

    15.5. Market Value Forecast, by Distribution Channel, 2016–2026

        15.5.1. Hospital Pharmacies

        15.5.2. Retail Pharmacies

        15.5.3. Online Pharmacies

    15.6. Market Value Forecast, by Country/Sub-region, 2016–2026

        15.6.1. GCC Countries

        15.6.2. Israel 

        15.6.3. South Africa

        15.6.4. Rest of Middle East & Africa

    15.7. Market Attractiveness Analysis 

        15.7.1. By Route of Administration 

        15.7.2. By Drug Class

        15.7.3. By Distribution Channel 

        15.7.4. By Indication

        15.7.5. By Country/Sub-Region

16. Competition Landscape

    16.1. Market Player - Competition Matrix

    16.2. Market Share Analysis, by Company (2017)

    16.3. Company Profiles

    16.4. Bayer AG

        16.4.1. Company Overview (HQ, Business Segments, Employee Strength)

        16.4.2. Financial Overview

        16.4.3. Product Portfolio

        16.4.4. SWOT Analysis

        16.4.5. Strategic Overview

    16.5. Boehringer Ingelheim International GmbH

        16.5.1. Company Overview (HQ, Business Segments, Employee Strength)

        16.5.2. Financial Overview

        16.5.3. Product Portfolio

        16.5.4. SWOT Analysis

        16.5.5. Strategic Overview

    16.6. Bristol-Myers Squibb Company

        16.6.1. Company Overview (HQ, Business Segments, Employee Strength)

        16.6.2. Financial Overview

        16.6.3. Product Portfolio

        16.6.4. SWOT Analysis

        16.6.5. Strategic Overview

    16.7. Daiichi Sankyo Company, Limited

        16.7.1. Company Overview (HQ, Business Segments, Employee Strength)

        16.7.2. Financial Overview

        16.7.3. Product Portfolio

        16.7.4. SWOT Analysis

        16.7.5. Strategic Overview

    16.8. Sanofi

        16.8.1. Company Overview (HQ, Business Segments, Employee Strength)

        16.8.2. Financial Overview

        16.8.3. Product Portfolio

        16.8.4. SWOT Analysis

        16.8.5. Strategic Overview

    16.9. Johnson & Johnson Services

        16.9.1. Company Overview (HQ, Business Segments, Employee Strength)

        16.9.2. Financial Overview

        16.9.3. Product Portfolio

        16.9.4. SWOT Analysis

        16.9.5. Strategic Overview

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Anticoagulants Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2026